Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00720304 · OUTCOME

Percent of Participants With Disease-Free Survival (DFS) at 3 Years

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck · Source last updated 2024-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent
Interval / dispersion
Not reported
Time frame
3 yrs after treatment

What was measured

Percent of participants with Disease-Free survival (DFS) at 3 years. Assessed from date of treatment to date of death or date of disease progression, and to date of last follow-up for those still alive and progression free. Disease-free Survival percentages were calculated using Kaplan-Meier estimates.

Analysis population: Participants enrolled in study

Groups in this outcome

Oral Erlotinib Hydrochloride

docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Oral Erlotinib Hydrochloride43

Reported measurements

Source class 1
Values in Percent · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Oral Erlotinib Hydrochloride69.5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        69.5
denoms
  1. counts
    1. group Id
      OG000
      value
      43
    units
    Participants
description
Percent of participants with Disease-Free survival (DFS) at 3 years. Assessed from date of treatment to date of death or date of disease progression, and to date of last follow-up for those still alive and progression free. Disease-free Survival percentages were calculated using Kaplan-Meier estimates.
groups
  1. description
    docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG000
    title
    Oral Erlotinib Hydrochloride
param Type
NUMBER
population Description
Participants enrolled in study
reporting Status
POSTED
time Frame
3 yrs after treatment
title
Percent of Participants With Disease-Free Survival (DFS) at 3 Years
type
PRIMARY
unit Of Measure
Percent

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice